23 March 2016
A new novel course of treatment aimed at improving the outcome of chemotherapy in cancer patients has been created in Sweden.
Researchers at Uppsala University have identified how inhibition of the growth factor VEGFA could be a potential means for significantly increasing the likelihood of positive outcomes for patients.
By inhibiting this molecule through a specific alteration of the protein complex, the accumulation of fluids in and around tumours in cancer patients can be minimised, thereby improving the ability of targeted drugs to work directly on the tumour.
Outlining the importance of the study's results, professor at the Department of Immunology, Genetics and Pathology at Uppsala University Lena Claesson-Welsh explained: "The specific mutation that we have studied allowed us to examine one of the signalling pathways in which VEGFA is involved.
"We therefore believe that a targeted inhibition of this specific signalling pathway ... might work better as a cancer therapy than the more general VEGFA inhibition that is used today."
Results of the study have been published in the scientific journal Nature Communications.
Posted by Jeanette Royston
Health News is provided by Axonn Media in collaboration with Spire Healthcare. Please note that all copy above is ©Axonn Media and does not reflect views or opinions of Spire Healthcare unless explicitly stated. Additional comments on the page from individual Spire consultants do not necessarily reflect the views or opinions of other consultants or Spire Healthcare.